Cytotoxic response of ovarian cancer cell lines to IFN-γ is associated with sustained induction of IRF-1 and p21 mRNA

SummaryIntereferon-γ (IFN-γ) has some anti-tumour activity in human ovarian cancer. This cytokine inhibited proliferation in three of four ovarian cancer cell lines in vitro. We then compared the action of IFN-γ in two cell lines, one sensitive and one resistant to its growth inhibitory effects. IFN-γ signalling appeared normal in both cell lines, with stat1 DNA binding activity detectable at 30 min. Continuous exposure to IFN-γ for 2–3 days was necessary for an irreversible effect on cell growth and apoptosis in cells sensitive to growth inhibition. During this time there was an increase in mRNA for the CKI p21, but no alterations in mRNA levels for other members of the CKI family. Maintenance of p21 mRNA required continuous mRNA synthesis. mRNA for the transcription factor IRF-1 was also induced in growth inhibited cells with similar kinetics to those observed for p21. Maximal induction of both p21 and IRF-1 mRNA was observed after 2–3 days IFN-γ exposure as the cells became committed to cell death. There was also a rapid increase in p21 and IRF-1 mRNA in cells resistant to the growth inhibitory effects of IFN-γ, but this increase was not maintained. Thus, continuous interaction with the IFN-γ receptor, together with a sustained induction of p21 and IRF-1, is associated with growth inhibitory and apoptotic effects of IFN-γ in ovarian cancer cells.

[1]  N. Andrews,et al.  A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. , 1991, Nucleic acids research.

[2]  M. Jaurand,et al.  Human Malignant Mesothelioma Cell Growth: Activation of Janus Kinase 2 and Signal Transducer and Activator of Transcription 1α for Inhibition by Interferon-γ , 1998 .

[3]  D. Hilton,et al.  The SOCS proteins: a new family of negative regulators of signal transduction , 1998, Journal of leukocyte biology.

[4]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[5]  G. Stark,et al.  Regulation of STAT‐dependent pathways by growth factors and cytokines , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  J. Smyth,et al.  Characterization and properties of nine human ovarian adenocarcinoma cell lines. , 1988, Cancer research.

[7]  A. Monnier,et al.  Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Marks,et al.  Transforming growth factor β1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells , 1994 .

[9]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Bast,et al.  Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[11]  F. Balkwill,et al.  Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat. , 1997, European journal of cancer.

[12]  D. Grandér,et al.  Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-α in hematopoietic cell lines , 1997, Oncogene.

[13]  P. Seth,et al.  The role of p27Kip1 in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells , 1997, Oncogene.

[14]  A. Monnier,et al.  Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  K Yuge,et al.  A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons. , 1998, Blood.

[16]  D. Jeoung,et al.  Effects of tumor necrosis factor-alpha on antimitogenicity and cell cycle-related proteins in MCF-7 cells. , 1995, The Journal of biological chemistry.

[17]  A. Riggs,et al.  Genomic sequencing. , 1993, Methods in molecular biology.

[18]  T. Taniguchi,et al.  IRF-1: the transcription factor linking the interferon response and oncogenesis. , 1997, Biochimica et biophysica acta.

[19]  T. Taniguchi,et al.  Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage , 1996, Nature.

[20]  P. Subramaniam,et al.  IFNα induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells , 1997, Oncogene.

[21]  W. A. Yeudall,et al.  Growth inhibitory concentrations of EGF induce p21 (WAF1/Cip1) and alter cell cycle control in squamous carcinoma cells. , 1996, Oncogene.

[22]  Xin-Yuan Fu,et al.  Cell Growth Arrest and Induction of Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Mediated by STAT1 , 1996, Science.

[23]  A. Deblasio,et al.  Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition , 1995, The Journal of cell biology.

[24]  J. Darnell,et al.  Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.